#NuGenerex

[ahmytricks]

NuGenerex Immuno-Oncology Announces the Launch of a New Corporate Website Other OTC:GNBT The “Complete Vaccine” for Cancer and Infectious Disease Ii-Key COVID Vaccine AE37 Immunotherapeutic Vaccine Management & Board of Directors…

[marketnewsfirst-blog]

Generex Biotech to Spin Out Nugenerex Immuno Oncology for Major Advancem...

[stocksnewsfeed]

Generex Biotechnology Announces Webcast and Invites All Shareholders to See and Listen to the Corporate Presentation from the 21st Annual H.C. Wainwright Global Healthcare Investment Conference

President & CEO Joe Moscato and Head of Research Richard Purcell Present the “New” Generex to the Investment Communityhttp://wsw.com/webcast/hcw5/gnbt/index.aspx MIRAMAR, Fla., Sept. 12, 2019 (GLOBE NEWSWIRE) — Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that the presentation delivered by Joe Moscato, President & Chief Executive Officer and Richard Purcell, Senior Vice President of Research to the H.C. Wainwright Global Healthcare Investment Conference on Monday September 9, 2019 is now available as a webcast. Mr. Moscato and Mr. Purcell presented the Generex corporate strategy and operating plan, ongoing plans for up-listing GNBT to Nasdaq, and the exciting news about the pending acquisition of ALTuCELL and partnerships with Arizona Endocrinology Center and Paradise Valley Family Medicine to advance the treatment and management of diabetes through the NuGenerex end-to-end model for integrated disease management.Mr. Moscato stated, “The partnerships we have established with the physician groups in Arizona under the banner of NuGenerex Health provide the platform for the future of Generex. We are re-establishing our diabetes franchise with our new model for integrated, comprehensive care with 65,000 patients, 25,000 of whom are insulin dependent. To make our model easy to understand, start with the complex, chronic patient, who accounts for the majority of healthcare costs in the U.S. With a focus on rebuilding the doctor/patient relationship we partner with specialists to provide ancillary business and clinical services through an MSO partnership with the physician groups; our MSO partners receive discount codes for NuGenerex products and services; we acquire companies like our new partner ALTuCELL to provide products and services that can be used by the physicians to take care of their patients; with the captive patient population to whom we are providing comprehensive specialty and primary care, NuGenerex Health intends to obtain to provide the end-to-end solutions under Medicare Advantage HMO contracts.”Mr. Purcell said, “As announced on Monday, we so pleased to have the opportunity to acquire ALTuCELL, which has superior, patented microencapsulation technology for cell therapy, and which has 5 years of safety data in humans. The microcapsules will be available for licensing to biotech company partners who are seeking a solution for immune rejection and implantation safety for their cellular therapies. The value of cell encapsulation technology is well recognized, as demonstrated by the recently announced acquisition of Semma Therapeutics by Vertex, so we are very happy to have ALTuCELL as part of the NuGenerex family of companies. Additionally, ALTuCELL’s proprietary Altsulin® (microencapsulated Sertoli Cells) cellular therapy offers a potential cure for Type I diabetes; in the pre-clinical translational research in animals from rodents to primates, the microencapsulated Sertoli Cells not only activated pancreatic islet cells to secrete insulin, but also a rebalancing of the autoimmune response. We look forward to working with ALTuCELL CEO Gary Harlem and his team to become a leader in the treatment of diabetes, and we invite you to join the webcast at http://wsw.com/webcast/hcw5/gnbt/index.aspx.”About Generex Biotechnology Corp. Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization, a network of pharmacies, clinical laboratory, and medical device companies with new and approved products. Our newly formed, wholly-owned subsidiary, NuGenerex Distribution Solutions (NDS), integrates our MSO network with a pharmacy network, clinical diagnostic lab, durable medical equipment company (DME-IQ) and dedicated call center.About Olaregen Therapeutix Olaregen Therapeutix, Inc. is a regenerative medicine company focused on the development, manufacturing and commercialization of products that fill unmet needs in the current wound care market. Generex aims to provide advanced healing solutions that substantially improve medical outcomes while lowering the overall cost of care. Olaregen’s first product introduction, Excellagen (flowable dermal matrix) is a topically applied product for dermal wounds and other indications. Excellagen is a FDA 510K cleared device for a broad array of dermal wounds, including partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/ grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns and skin tears) and draining wounds, enabling Olaregen to market Excellagen in multiple vertical markets. Additionally, Excellagen can serve as an Enabling Delivery Platform for pluripotent stem cells, antimicrobial agents, small molecule drugs, DNA-Based Biologics, conditioned cell media and peptides. Olaregen’s initial focus will be in advanced wound care including diabetic foot ulcers (DFU), venous leg ulcers and pressure ulcers. Future products focusing on innovative therapies in bone and joint regeneration comprise the current pipeline. Generex’s mission is to become a significant force in regenerative medicine and advance the science of healing.About our Service-Disabled Veteran-Owned Small Business (SDVOSB) This a Service-Disabled Veteran-Owned Small Business (SDVOSB) that specializes in the sale, marketing, and distribution of innovative medical products through a nationwide network of veteran owned distribution services.About Pantheon MedicalPantheon Medical is a manufacturer of a physician friendly, “all-in-one”, integrated kit that includes plates, screws, and tools required for orthopedic surgeons and podiatrists conducting foot and ankle surgeries. Generex is developing and submitting several new product lines to the FDA which will include cannulated surgical screws, plates, and implants.About MediSource Partners MediSource Partners is a 10-year-old private company, currently contracted with over 25 vendors (including Pantheon Medical) for nationwide distribution of implants and devices for spine, hips, knees, foot, ankle, hand, and wrist surgeries. Additional product lines include biologics (blood, bone, tissue, stem cells), durable medical equipment, and soft goods. Generex also supplies kits to process bone marrow aspirates and platelet rich plasma biologics at the time of surgery.Cautionary Note Regarding Forward-Looking StatementsThis release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as “expects,” “plan,” “believes,” “will,” “achieve,” “anticipate,” “would,” “should,” “subject to” or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.Generex Contact:Generex Biotechnology CorporationJoseph Moscato 646-599-6222Todd Falls 1-800-391-6755 Extension 222 investor@generex.com 

The post Generex Biotechnology Announces Webcast and Invites All Shareholders to See and Listen to the Corporate Presentation from the 21st Annual H.C. Wainwright Global Healthcare Investment Conference appeared on Stocks News Feed.

source https://stocksnewsfeed.com/globenewswire/generex-biotechnology-announces-webcast-and-invites-all-shareholders-to-see-and-listen-to-the-corporate-presentation-from-the-21st-annual-h-c-wainwright-global-healthcare-investment-conference/

[maxgainzzz]

Generex Biotechnology Corp. (GNBT: OTCQB) | Generex Biotechnology Welcomes MediSource Partners to the NuGenerex Family of Companies

from OTC Markets Group - News, Filings & Corporate Actions http://www.otcmarkets.com/stock/GNBT/news?id=235994

[tspeciale]

Generex Subsidiary NuGenerex Diagnostics Announces CE-Mark Certification for its Rapid Point-of-Care Express II Syphilis Treponemal Assay

http://dlvr.it/QxNtFT

[randybenedict]

Generex Biotech inks $1m deal to acquire distributor Medisource Partners

Generex Biotechnology said yesterday that it inked a deal to acquire medical and surgical product distributor Medisource Partners in a deal worth approximately $1 million.

Miramar, Fla.-based Generex said that the deal includes all assets of Medisource including its business operations, accounts receivable, inventory, contracts and real estate for $1 million worth of Generex stock, as well as additional cash and stock considerations for achieving certain sales and profit milestones.

“The strategic acquisition of Medisource Partners provides Generex with a value-added service model that fits the corporate mission of NuGenerex Distribution Solutions, adding immediate revenues and profits, while providing significant upside as we integrate the medical and surgical supply business into our current and future MSO networks. The extensive lines of surgical and biological products offered in the Medisource catalogue will enable us to expand our offerings to now include hospital systems, as well as our MSO partners. Our management services will not only integrate purchasing and billing, but will provide better pricing and access to new products, especially biologics, including platelet rich plasma, bone marrow aspirate, cord blood, and bone implants. We are excited that the acquisition of Medisource will provide access to a whole new line of products that not only enhances our current MSO network in the five states, but will eventually support the expansion of our MSO network into 27 states. We are in the process of completing the due diligence on this acquisition, with plans to close the transaction in the coming weeks,” Generex CEO Joe Moscato said in a press release.

Medisource Partners is currently contracted with more than 25 vendors to distribute implants and devices for spinal, hip, knee, foot, ankle, hand and wrist surgeries. The company distributes devices including biologics, durable medical equipment and soft goods, Generex said.

“MediSource Partners was founded in 2009 and designed to be unique amongst its competitors by operating as a service-focused, ‘one stop shop’ for the healthcare professionals it serves. With over 25,000 products in its catalogue, including thirteen lines dedicated to spine, Medisource prides itself on its ability to service everything from small private practices across several disciplines, to entire hospital systems. The large and broad-based inventory allows our client physicians to ‘customize’ their operating environment by selecting and implementing the hardware, biologics, soft goods and ancillary tools they feel most confident in and comfortable with. In addition, the ‘one stop shop’ model reduces the burden placed on support staff tasked with managing multiple reps from multiple vendors and shortens the distribution chain to reduce costs and potential redundancies. The success of this model is demonstrated in Medisource’s ability to offer this client-focused, low-impact service at a pricing matrix often below even standard GPO pricing, thus increasing client profitability and productivity,” Medisource CEO Travis Bird said in a prepared statement.

The post Generex Biotech inks $1m deal to acquire distributor Medisource Partners appeared first on MassDevice.

from MassDevice http://bit.ly/2FmFMOc

[otcsocialnetwork]

$NOUV – Multiple Shots on Goal in Multi-Billion Dollar Markets 

$NOUV – Multiple Shots on Goal in Multi-Billion Dollar Markets  January 08, 2019 – “Separately, management believes that based on feedback from those that were involved in the aforementioned study that the Kali-Extracts extracts may be superior to those of GW Pharmaceuticals (NASDAQ – GWPH – NR), the maker of Epidiolex. Plus, management proffered that as part of the development of its COPD therapies through its US Cannabis Health Partnership with Puration and Nouveau Pharma (OTC – NOUV – NR) the potential for Kali-Extracts to harness the patented RapidMist buccal cavity drug administration technology of Generex Biotechnology (OTC – GNBT – NR) would be a boon to all involved. Kali-Extracts’s joint venture agreement named US Cannabis Health with Puration and Nouveau was formed to combine their respective resources for the specific purpose of developing partnerships with major pharmaceutical companies to produce medical cannabis therapies.  Wellness  In the wellness arena, the early affirmation of its extract’s efficacy has occurred via sales of Puration Inc.’s CBD-infused beverage product which is based on Kali-Extracts’s IP. In fact, Puration could reach $1M in sales this year and $3M-$5M next year. Still, that is just the beginning. Various joint ventures and new product introductions in which Kali-Extracts has engaged are likely sources of near-term revenue for Kali-Extracts in the CBD-infused product market. For example, as noted above, Puration and Kali-Extracts are part of a joint venture company called US Cannabis Health which was formed for the purpose of developing and marketing pharmaceutical applications and non-pharmaceutical wellness concentrates derived from Kali-Extracts’s patented extraction process. Puration, currently the sole licensee of the process will be producing the NuGenerex CBD HydroHealth High Alkaline Water. As part of this arrangement, Kali-Extracts will be developing custom CBD extracts for Puration to infuse into the NuGenerex CBD HydroHealth High Alkaline Water. The Company is also producing its own products. Last month, Kali-Extracts announced it was launching its own line of hemp-derived CBD infused candies and vapes under the brand name HEMP4MULA. With an initial wholesale order pending Kali-Extracts’s completion of its first production run, the company expects to see HEMP4MULA CBD Gum on sale at retail later this month. Kali-Extracts’s Hemp4mula CBD Infused Chewing Gum will come in a blister back of 8 pieces with 10 mg each of hemp-derived CBD. Mints and gummies infused with CBD are expected to follow soon thereafter. HEMP4MULA vapes are also coming soon. Kali-Extracts and Nouveau recently announced an agreement to expand NOUV’s current cultivation operations to include 100 adjacent acres dedicated to growing hemp under the new Farm Bill legalizing hemp farming just signed into law by President Trump. Kali-Extracts will construct a CBD extraction facility on site based on its proprietary and patented extraction process. In addition to the outdoor hemp cultivation, Nouveau will build a state-of-the-art greenhouse operation intended for the development of a proprietary hemp cultivar. Nouveau has a cannabis cultivation operation with facilities in the U.S. and Canada. The objective of the partnership is to develop a proprietary pharmaceutical grade hemp cultivar in addition to being a source of hemp supply for a myriad of industries in what both companies anticipate to be exploding demand in 2019.  KEY FIGURES  As noted above, the Company’s innovative extraction technology is already bearing fruit. It can be quantified in the success of the Puration beverages. Puration currently produces EVERx CBD Sports Water, the leading CBD infused water in the sports nutrition market. Puration has trailing twelve-month revenues of approximately $1 million. However, due to the aforementioned relationship with Generex, Puration received a $1M order at year-end related to the launch of NuGenerex CBD HydroHealth High Alkaline Water. It should be noted that $300,000 of the order is earmarked to Kali-Extracts as a CBD extraction contract. Clearly, the Puration relationship is a near term sales driver as its potential $3M – $5M in revenue for 2019 would certainly contribute to Kali-Extracts’ financials. Separately, the Company was awarded a $100,000 wholesale order of its Hemp4mula CBD Infused Chewing Gum. The wholesale buyer plans to have Hemp4mula CBD Infused Chewing Gum available for sale at select retail drugstore locations and through the soon to be launched USMJ E-commerce Site from North American Cannabis Holdings, Inc. (OTC – USMJ – NR). Finally, the Company and Nouveau anticipate up to $5 million in revenue from their hemp cultivation and extraction venture. On the heels of the hemp legalization, industry sources suggest that hemp farming could yield $50,000 per acre from the combination of CBD extraction and other uses of hemp. Thus, the 100-acre hemp cultivation operation could yield $5 million.  http://www.goldmanresearch.com/201901081229/O…ustry.html http://dlvr.it/QwFCBy

[mikemortgage]

Generex Biotechnology Receives IND Approval from FDA for Phase II Combination Study using AE37 plus Keytruda® (pembrolizumab) for the Treatment of Triple Negative Breast Cancer

MIRAMAR, Fla. — Generex Biotechnology Corporation (OTCQB:GNBT) today announced that the FDA had reviewed the company’s investigational new drug (IND) application and given notification that the study can proceed. The study: A Phase II Clinical Trial of Pembrolizumab (Keytruda®) in Combination with the AE37 Peptide Vaccine in Patients with Metastatic Triple Negative Breast Cancer, is sponsored by Generex and conducted under a collaboration agreement with Merck and a clinical trial agreement with the NSABP Foundation, Inc. (NSABP).

The combination study builds on previous clinical studies of both AE37 and Keytruda®. AE37, a cancer vaccine, was the subject of a 300 patient prospective, randomized and single-blinded Phase II study in patients with breast cancer. That study showed a strong trend toward reduced relapses,particularly in patients with triple negative breast cancer. Keytruda® also has shown encouraging results in patients with triple negative breast cancer when used as monotherapy. The complementary mechanisms of action of the two drugs suggest the combination may have the potential to be better than either alone.

AE37 is unique among therapeutic cancer vaccines in that it ensures specific activation of CD4+ T helper cells, which are critical in generating an effective immune response. Its improved immunological potency, along with an excellent safety profile, offers particular advantages for combination studies. In addition to the Phase II study in breast cancer patients, AE37 also has been tested in a Phase I study in prostate cancer patients. AE37 treated patients have consistently displayed a robust, long-lasting and specific response to the vaccine.

Liesha Emens, M.D., Ph.D., Principal Investigator for the study and Professor of Medicine at the University of Pittsburgh Medical Center commented: “So far, metastatic triple negative breast cancer patients treated upfront with immunotherapy benefit clinically from immune checkpoint immunotherapy only if their tumors contain PDL1+ cells. Increasing the number of patients with immune-activated tumors should bring the benefit of immunotherapy to even more patients. This Phase II trial will test whether the AE37 vaccine may trigger immunity in triple negative breast cancer patients, priming them for clinical benefit from immune checkpoint blockade.”

Eric von Hofe, President of NuGenerex-ImmunoOncology commented: “We are gratified to see this important trial moving forward. While we have tested AE37 in breast and prostate cancer patients, there is good rationale for inclusion of AE37 in the treatment regimen of a variety of additional cancer types of high unmet need. Gastric, colon, ovarian and bladder cancers all express the same tumor target expressed in breast and prostate cancer that AE37 activates the immune system to recognize.”

About AE37

AE37 is an investigational therapeutic cancer vaccine being developed to treat certain types of breast cancer. It is a combination of portions of two proteins that together stimulate the immune system to fight cancer cells.

Up to 80 percent of breast cancers express some level of a protein called HER2. While treatments exist to target HER2 in breast cancer patients with the highest level of HER2 expression (roughly 25%), the majority of patients who have lower levels of expression have more limited treatment options. AE37 consists of a protein derived from the HER2 protein combined with a portion of the MHC class II associated invariant chain which has been termed Ii-Key.

AE37 does not directly target HER2, but rather acts as a vaccine to activate the immune system to recognize the HER2 protein, which is expressed on cancer cells as foreign. AE37 ensures activation of CD4-positive lymphocytes, immune cells that are important in stimulating both the antibody response (antibodies against HER2) and cellular responses directed against the HER2 protein in breast cancer cells. The Ii-Key peptide is coupled with the HER2 protein to ensure a more robust and long-lasting response.

About Generex Biotechnology

Generex is a strategic, diversified healthcare holdings company with offerings in a variety of arenas, including diagnostics, medical devices, and pharmaceutical development. The Company’s direct-to-patient services support its strategy of all-inclusive access to doctors, diagnostics, therapeutics, and additional health-related services to greatly improve the patient experience in receiving care. On the provider side, Generex’s management services remove administrative burdens in multiple provider settings, including private practice and hospital, allowing doctors to devote more time to patient care. Revenue from the Company’s subsidiaries supports the clinical advancement of its wholly owned therapeutic products with a focus in immunotherapeutics based on stimulating critical members of the immune response, known as T helper cells, and in its proprietary buccal administration of insulin.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as “expects,” “plan,” “believes,” “will,” “achieve,” “anticipate,” “would,” “should,” “subject to” or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181212005519/en/

Contacts

Generex Biotechnology Corporation

Joseph Moscato 646-599-6222

Todd Falls 800-391-6755 Extension 222

investor@generex.com

Russo Partners

Investor / Media Contacts:

Alex Fudukidis (646) 942-5632 alex.fudukidis@russopartnersllc.com

Caroline Cunningham (212) 845-4292 Caroline.Cunningham@russopartnersllc.com

from Financial Post https://ift.tt/2PyuaIo via IFTTT Blogger Mortgage Tumblr Mortgage Evernote Mortgage Wordpress Mortgage href="https://www.diigo.com/user/gelsi11">Diigo Mortgage

[pharmamktnet]

Generex Launches NuGenerex Medical Marketing

Generex Launches NuGenerex Medical Marketing

MIRAMAR, Fla.–(BUSINESS WIRE)–Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce the launch of NuGenerex Medical Marketing (NMM) (https://nugenerexmedicalmarketingllc.com/) to provide in-depth patient health management services, including patient identification, acquisition and onboarding, as well as ongoing patient…

[marketnewsfirst-blog]

generex immunotherapeutic vaccine program

[maxgainzzz]

Generex Biotechnology Corp. (GNBT: OTCQB) | Generex Biotechnology Introduces Pantheon Medical, the Newest Member of the NuGenerex Family of Companies

from OTC Markets Group - News, Filings & Corporate Actions http://www.otcmarkets.com/stock/GNBT/news?id=235823

[maxgainzzz]

Generex Biotechnology Corp. (GNBT: OTCQB) | Generex Signs Letter of Intent with Kiromic to Merge with NuGenerex Immuno-Oncology Forming a Multi-Platform Clinical Stage Immunotherapy Company

from OTC Markets Group - News, Filings & Corporate Actions http://www.otcmarkets.com/stock/GNBT/news?id=232600

[maxgainzzz]

Generex Biotechnology Corp. (GNBT: OTCQB) | Generex Investor Conference Call Recording Now Available Online Detailing 1:1 Stock Dividend, Merger for NuGenerex Immuno-Oncology and Go Forward Plans

from OTC Markets Group - News, Filings & Corporate Actions http://www.otcmarkets.com/stock/GNBT/news?id=232441